Sinovac Biotech, Ltd.: stock overview

SVANASDAQHealthcare · Pharmaceutical Preparations

Price

$6.47

November 12, 2026Market cap $465M

DCF calculator

What Ploutos Investor adds for Sinovac Biotech

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • A figure that did not match the numbers it is built from has been left out.

In short

Sinovac Biotech had revenue of $386M in the fiscal year to December 31, 2025 and a net loss of $60M. Revenue fell by 5.4% a year on average over the last 5 years. It holds more cash than debt, by $5.5B. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 12, 2026.

Its SEC filings
Market cap
$465M
71.86M shares
P/E
–
Revenue, fiscal year
$386M
-5.4% a year over 5 years
Net margin
-15.5%
2025: -51.5%, above 21% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

-9.4% a year over 2 years

  • 202520-F
    Revenue$386M
  • 202420-F
    Revenue$361M
  • 202320-F
    Revenue$470M

Fiscal years in figures

SVA's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 
$465M
Enterprise value 
–
P/E 
–
EV / EBIT 
–
EV / Revenue 
–
P/B 
0.1
FCF yield 
–
Earnings yield 
–

Profitability

Gross margin 
67.9%
Operating margin 
-127.0%
Net margin 3-year median: -2.9%
-15.5%
ROIC 
-7.9%
ROIC, 5-year average 
26.1%
ROE, fiscal year 
-1.3%

Growth

Revenue, yearly change 
+6.8%
EPS, yearly change 
-165.4%
FCF, yearly change 
–
Revenue, average a year 
-5.4%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$6.0B
Total debt 
$506M
Of which operating leases 
$11M
Net cash 
$5.5B
Net debt / EBITDA 
–
Interest cover 
-49.9x
Current ratio 
–

Balance sheet of December 31, 2025.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
850.08%
Shares, yearly change 
0.0%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

67.9%

Above 80% of the 141 companies in its industry, and 85% of all.

Operating margin

-127.0%

Above 14% of the 285 companies in its industry, and 3% of all.

Net margin

-51.5%

Above 21% of the 302 companies in its industry, and 7% of all.

ROE

-4.5%

Above 50% of the 267 companies in its industry, and 24% of all.

ROA

-2.3%

Above 50% of the 313 companies in its industry, and 25% of all.

Revenue growth

6.8%

Above 52% of the 292 companies in its industry, and 52% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
SINOVAC BIOTECH LTD
CIK
1084201
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
71.86M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Sinovac Biotech's filings show?

These are Sinovac Biotech's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about SVA

Didn't find what you were looking for?

Ask us
What is SVA's market cap?

Sinovac Biotech, Ltd.'s market cap is $465M, at a price of $6.47 on November 12, 2026 and 71.86M shares.

How much revenue does SVA have?

Sinovac Biotech had revenue of $386M in the fiscal year to December 31, 2025. Over the last 5 years it changed by -5.4% a year on average.

Does SVA pay a dividend?

No. Sinovac Biotech paid no regular dividend over the last 12 months.

Where do the figures come from?

From Sinovac Biotech, Ltd.'s SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.